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Serotonin (5-HT) neurons are involved in wake promotion and exert a strong inhibitory inﬂuence on
rapid eye movement (REM) sleep. Such effects have been ascribed, at least in part to the action of 5-HT at
post-synaptic 5-HT1A receptors (5-HT1AR) in the brainstem, a major wake/REM sleep regulatory center.
However, the neuroanatomical substrate through which 5-HT1AR inﬂuence sleep remains elusive. We
therefore investigated whether a brainstem structure containing a high density of 5-HT1AR mRNA, the
GABAergic Gudden's dorsal tegmental nucleus (DTg), may contribute to 5-HT-mediated regulatory
mechanisms of sleep-wake stages.
We ﬁrst found that bilateral lesions of the DTg promote wake at the expense of sleep. In addition, using
local microinjections into the DTg in freely moving mice, we showed that local activation of 5-HT1AR by
the prototypical agonist 8-OH-DPAT enhances wake and reduces deeply REM sleep duration. The speciﬁc
involvement of 5-HT1AR in the latter effects was further demonstrated by ex vivo extracellular recordings
showing that the selective 5-HT1AR antagonist WAY 100635 prevented DTg neuron inhibition by 8-OH-
DPAT. We next found that GABAergic neurons of the ventral DTg exclusively targets glutamatergic
neurons of the lateral mammillary nucleus (LM) in the posterior hypothalamus by means of anterograde
and retrograde tracing techniques using cre driver mouse lines and a modiﬁed rabies virus.
Altogether, our ﬁndings strongly support the idea that 5-HT-driven enhancement of wake results from
5-HT1AR-mediated inhibition of DTg GABAergic neurons that would in turn disinhibit glutamatergic
neurons in the mammillary bodies. We therefore propose a Raphe/DTg/LM pathway as a novel
regulatory circuit underlying 5-HT modulation of arousal.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).7n, facial nerve; 8-OH-DPAT, 8-hydroxy-2-(di-n-propylamino)-tetraline; aCSF, artiﬁcial cerebrospinal ﬂuid; AD, anterior
p, cerebral peduncle; DRc, caudal part of the dorsal raphe nucleus; DRi, interfascicular part of the dorsal raphe nucleus;
fasciculus retroﬂexus; GAD67, glutamate decarboxylase, 67 kDa type; HD, head direction cells; HDC, histidine decar-
scus; LC, locus cœruleus; LDTg, laterodorsal tegmentum; LM, lateral mammillary nucleus; Mo5, motor trigeminal nu-
odorsal tegmental nucleus; PHA-L, Phaseolus vulgaris-leucoagglutinin; pm, principal mammillary tract; PPTg,
scp, superior cerebellar peduncle; REM, rapid eye movement; TMN, tuberomammillary nucleus; VGLUT2, vesicular
logy, Universite Libre de Bruxelles, ULB Neuroscience Institute UNI, 808route de Lennik, 1070, Brussels, Belgium.
Pierre et Marie Curie, Inserm, CNRS, Neuroscience Paris Seine (NPS), Institut de Biologie Paris Seine (IBPS), 9Quai Saint
re), pbonnavi@ulb.ac.be (P. Bonnavion).
rk.
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Serotonergic neurons located in the raphe nuclei belong to the
ascending arousal system that triggers cortical activation during
wake. Indeed, most of serotonergic neurons discharge maximally
during wake, decrease their ﬁring rate during non-rapid eye
movement (NREM) sleep and are silent during REM sleep (McGinty
and Harper, 1976; Rasmussen et al., 1984; Sakai, 2011). As a result,
extracellular 5-HT levels are higher during wake than during sleep
both in the raphe nuclei and in brain areas targeted by 5-HT neu-
rons (Portas et al., 2000). Importantly, enhancing 5-HT tone by
systemic administration of selective serotonin reuptake inhibitors
(SSRIs) has been repeatedly reported to inhibit REM sleep across
species (Slater et al., 1978; Sommerfelt et al., 1987; Maudhuit et al.,
1994; Monaca et al., 2003). In addition, recent ﬁndings have shown
that 5-HT raphe neurons inhibit the pathological intrusion of REM
sleep into wake in a mouse model of the sleep disorder narcolepsy
(Hasegawa et al., 2017). Taken together, these observations suggest
that 5-HT neurons promote cortical activation whilst impeding
REM sleep onset during wake.
Serotonergic modulation of sleep/wake stages involves complex
modalities of action andmultiple receptors. Yet, a key role has been
assigned to 5-HT1A receptors (5-HT1AR) in sleep regulation as
knock-out mice that do not express these receptors exhibit higher
amounts of REM sleep and altered REM sleep homeostasis (Boutrel
et al., 2002). Furthermore, 5-HT1AR underlie the SSRI-induced
suppression of REM sleep. Indeed, the classical REM sleep deﬁcits
due to citalopram administration are not observed in 5-HT1AR
knock-out mice and are also markedly reduced after the pharma-
cological blockade of 5-HT1AR in wild-type mice (Monaca et al.,
2003). 5-HT1AR are Gi/Go-protein-coupled receptors present on
both somas and dendrites of serotonergic neurons in raphe nuclei
(somatodendritic autoreceptors; Sotelo et al., 1990) and on target
neurons receiving 5-HT projections (postsynaptic receptors; Kia
et al., 1996; Riad et al., 2000). Through mediation of 5-HT inhibi-
tory neurotransmission, stimulation of 5-HT1AR via systemic
administration of selective agonists has been consistently shown to
markedly enhancewake and to decrease sleepwith amain effect on
REM sleep occurrence (Portas and Grønli, 2008). Whether these
effects could be attributed to post-synaptic 5-HT1AR or autor-
eceptors is still debated. Thus, contradictory effects were observed
with local activation of 5-HT1A autoreceptors in the dorsal raphe as
it either enhanced (Bjorvatn et al., 1997) or did not modify (Sakai
and Crochet, 2001) REM sleep. However, the effects of the 5-
HT1AR agonist ipsapirone on sleep persisted after the selective
destruction of 5-HT neurons by the neurotoxin 5,7-
dihydroxytryptamine (Tissier et al., 1993), which would rather
suggest a primary role of post-synaptic 5-HT1AR over autoreceptors
in mediating 5-HT regulations of sleep/wake behavior.
Despite the established role of 5-HT1AR in sleep regulation, the
neural mechanisms and circuits by which the latter receptors are
involved remain unclear. The brainstem is critical for the generation
and maintenance of wake and REM sleep (Jouvet, 1962; Boissard
et al., 2003; Lu et al., 2006; Cox et al., 2016). Multiple nuclei have
been identiﬁed and involved in these functions but none of them
express signiﬁcant levels of post-synaptic 5-HT1AR (Bonnavion
et al., 2010). In contrast, we characterized a pontine nucleus con-
taining a high density of 5-HT1AR mRNAs, the Gudden's dorsal
tegmental nucleus (DTg), which is mostly GABAergic (Bonnavion
et al., 2010). This led us to investigate whether the latter nucleus
is involved in the 5-HT1AR-mediated inhibition of sleep in mice. For
this purpose, we ﬁrst conﬁrmed the presence of 5-HT1AR in
GABAergic neurons of the DTg. Next, we analyzed the consequences
of DTg lesions on sleep/wake states and investigated the role of 5-
HT1AR in the DTg on sleep regulation using local pharmacologicalinjections of the 5-HT1AR agonist 8-OH-DPAT. To further evaluate
the speciﬁc involvement of 5-HT1AR, we tested ex vivo the effects of
8-OH-DPAT on the activity of DTg neurons. Finally, we tracked the
DTg connections throughout the brain to identify its downstream
targets using anterograde and retrograde tracing methods
including rabies-mediated trans-synaptic tracing and cre-based
cell-type-speciﬁc targeting (Mebatsion et al., 1996; Kohara et al.,
2014). Our ﬁndings reveal an unexpected contribution of the DTg
in the 5-HT1AR-mediated promotion of wakefulness through pro-
jections to glutamatergic neurons of the hypothalamic lateral
mammillary nucleus (LM).
2. Materials and methods
2.1. Animals and surgeries
2.1.1. Animals and housing
In this study, VGLUT2-ires-cre knock-in (C57BL/6J background;
The Jackson Laboratory; JAX:016963), transgenic 5-HT1A-iCre/R26R
(C57Bl/6J background; originally obtained from the colony of
author FT; Sahly et al., 2007) and C57Bl/6J (reCentre d’elevage R.
Janvier, Le Genest St Isle, France) adult (2-4 months-old) or juvenile
(3-5weeks-old)malemicewere used. 5-HT1A-iCre/R26Rmicewere
obtained by crossing 5-HT1A-iCre transgenic mice with R26R re-
porter mice harboring a LacZ transgene (Sahly et al., 2007). To avoid
genetic drifts, mouse colonies were refreshed once a year with new
commercial breeders. Micewere housed under standard conditions
(12 h light-dark cycle, starting at 7:00 a.m.; 23± 1 C ambient
temperature; 60% relative humidity; food and water ad libitum). All
experiments were performed in strict conformity with the Euro-
pean Union laws and policies for use of animals in neuroscience
research (European Committee Council Directive 86/609/EEC), and
with the Ethical Committee for Preclinical Research (nb 5) of the
French Ministry of Research and High Education (articles
R.214e124, R.214e125).
2.1.2. Electrolytic lesions
Adult male mice (n¼ 21; 8 weeks-old, body weight: 23e26 g)
were anesthetized with ketamine/xylazine (K/X) [50 and 2mg/kg,
respectively, intraperitoneal (i.p.) injection] and placed in a ste-
reotaxic apparatus. Electrolytic lesions of the DTg were made
bilaterally by passing direct current (Constant current isolated
stimulator, DS3, Digitimer Ltd, Welwyn Garden City, Hertfordshire,
UK) with a monopolar electrode (100 mm in diameter, 0.2mm
exposed tip). Thirty pulses (1 s) of 60 mA were delivered at the
following stereotaxic coordinates, from bregma (Franklin and
Paxinos, 2008): 1) 5.0mm anteroposterior (AP); ±0.25mm
lateral (L); 2.6mm and 2.9mm ventral from brain surface (V);
2) 5.4mm AP; ±0.25mm L; 2.8mm and 3.1mmV. No current
was delivered through the electrode in the control group.
2.1.3. Intracerebral cannula implantations
As for electrolytic lesions, adult male mice (n¼ 17; 8 weeks-old,
body weight: 23e26 g) were anesthetized with K/X and placed in a
stereotaxic apparatus. A 26-gauge stainless steel cannula guide
(Plastic one Inc, Roanoke, VA) with its tip aimed 1.0mm above the
DTg [from bregma (Franklin and Paxinos, 2008): 5.3mm AP;
0.2mm L; and 1.9mmV] was anchored to the skull with dental
acrylic cement. A dummy cannula was screwed in the cannula
guide to avoid clogging.
2.1.4. Surgical procedure for sleep monitoring
After removal of the lesion electrode or implantation of the
canula guide, mice were implanted with electroencephalogram
(EEG), electrooculogram (EOG) and electromyogram (EMG)
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from two electrodes located on the frontal (from bregma: þ2 mm
AP; þ2 mm L) and parietal (from lambda þ1 mm AP; þ2 mm L)
cortices. EOG signals were recorded from two electrodes located
subcutaneously on each side of the orbit, and EMG signals were
recorded from two electrodes inserted in the neck musculature to
record postural tone. All electrodes were soldered to a mini-
connector (Antelec, La Queue en Brie, France). Dental acrylic
cement was used to anchor the electrodes to the skull. Mice were
allowed to recover for 7e10 days and then acclimated to the
recording cables for a further 7 days in individual recording
chambers.
2.2. Pharmacological treatment
For freely moving intracerebral drug administration, mice were
ﬁrst habituated for 7 days to daily gentle handling to minimize
stress during injection. A 33-gauge stainless steel cannula was
inserted into the implanted guide with a 1mm protruding tip. At
10:00 a.m. (ZT 3), the 5-HT1AR agonist 8-hydroxy-2-(di-n-propy-
lamino)-tetralin (8-OH-DPAT, 20 mM; 250 pg in 50 nl of 0.9% sterile
saline; Sigma, St. Louis, MO) or 0.9% sterile saline (50 nl) was
infused at a ﬂow rate of 50 nl/min. This amount of 8-OH-DPAT was
chosen as lower doses (2.5 and 25 pg) did not signiﬁcantly affect
vigilance states (Supplementary Table 1). The cannula was left in
place 3min before mice were placed back in the recording cham-
bers and recordings started.
2.3. Polygraphic recordings and analysis
EEG, EOG and EMG signals derived from the surgically implan-
ted electrodes were ampliﬁed, sampled at 100Hz (EOG) or 200 Hz
(EMG and EEG), and digitized by an Embla Module (Medcare,
Reykjavik, Iceland). All scoring was performed manually based on
the visual signature of EEG, EOG and EMG waveforms of 5 s (mi-
croinjections) or 10 s (lesion) epochs to deﬁne wakefulness
(WAKE), NREM or REM sleep following classical criteria (Boutrel
et al., 2002) using sleep analysis Somnologica® software (Med-
care, Reykjavik, Iceland). Amounts of time (also called amounts in
the text) spent in WAKE, NREM and REM sleep were expressed as
minutes per 1, 2 or 12 h intervals. NREM sleep latency was deﬁned
as time elapsed between the beginning of the recording and the
ﬁrst NREM sleep bout lasting at least 30 s. For REM sleep latency,
we determined the time elapsed between the beginning of the ﬁrst
NREM sleep bout and the occurrence of the ﬁrst REMS bout lasting
at least 20 s.
2.4. Ex vivo electrophysiological recordings
2.4.1. Slice preparation
Male C57/Bl6 mice, 3e5 weeks-old, were anesthetized with
halothane and killed by decapitation. Brains were removed and
220 mm coronal DTg slices were made using a vibratome (Leica
VT1000S) in ice-cold (4 C) dissection solution containing (in mM):
choline chloride 140, KCl 2.5, NaH2 PO4 1.25, MgCl2 7, CaCl2 0.5,
NaHCO3 25, glucose 14, saturated with 95% O2 and 5% CO2. Slices
were transferred to the recovery chamber and incubated in artiﬁcial
cerebrospinal ﬂuid (aCSF) containing (in mM): NaCl 127, KCl 2.5,
NaH2PO4 1.25, MgCl2 1, NaHCO3 26, D-glucose 10, CaCl2 2, bubbled
with a mixture of 95% O2 and 5% CO2 at a pH of 7.3 (300e316
mOsm). After an initial recovery period of 1 h at 34 C, slices were
maintained at room temperature.
Individual slices were transferred to a thermoregulated
(30e32 C) chamber, maintained immersed with a nylon grid and
continuously superfused at a rate of 1,5e2ml/minwith oxygenatedaCSF. Neurons were identiﬁed with a 63water immersion
objective from Zeiss Axioskop microscope (Axioskop 2FS Plus; 140
Zeiss, Oberkochen, Germany) with an infrared CCD camera (X-
ST70CE, Hamamatsu Photonics KK, Hamamatsu, Japan) for extra-
cellular or whole-cell recordings. For recording in mouse coronal
slices, we chose sites strictly conﬁned to the DTg (see Anatomical
validation section below) avoiding DR midline neurons. When
possible, conﬁrmation of the neurons location was assessed with
biocytin injection at the end of the recordings (N¼ 15). A ﬁrst series
of cells were recorded in loose-seal conﬁguration, and a second
series in whole-cell conﬁguration to further examine basic char-
acteristics of mouse DTg neurons. Borosilicate-glass patch elec-
trodes [4e6MU, (Hilgenberg GmbH, Malsfeld, Germany)] were
ﬁlled with a solution containing (in mM): KMeSO3 125, KCl 12,
CaCl2 0.022, MgCl2 4, HEPES 10, EGTA 0.1, Na2-phosphocreatine 5,
Mg2-ATP 4, Na2-GTP 0.5 (pH of 7.2, 292 mOsm). An Ag/AgCl wire
was used as reference electrode. Currents were recorded using an
EPC-10 patch clamp ampliﬁer (HEKA, Lambrecht, Germany) and
PatchMaster acquisition software (HEKA).
2.4.2. Loose-seal patch recordings
Extracellular recordings of spontaneous action potentials were
acquired in voltage clamp mode (0mV) in loose-seal conﬁguration.
Signals were sampled at 20 kHz with a gain of 2mV/pA and low-
pass ﬁltered at 2.9 kHz. Standard off-line detection of sponta-
neous action potentials was performed with Axograph X software
(Axon Instruments Inc., Foster City, CA). For this analysis, we
generated an action potential to scan the recording trace for similar
waveforms. All matching events were stored and, if false positive
events were detected, they were discarded on the basis of their
amplitude or kinetics. Spontaneous neuronal activity was moni-
tored during 5e10min from the beginning of the recording during
baseline aCSF perfusion for each neuron. Then, 8-OHDPAT (300 nM;
Tocris Bioscience) and/or the 5-HT1AR antagonist N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexane
carboxamide (WAY 100635; 1 mM; Tocris Bioscience) were bath-
applied by switching the perfusion system. Agonist and antago-
nist concentrations were used based on previous work showing
speciﬁc involvement of 5-HT1AR signaling (Loucif et al., 2006). Stock
solutions were prepared in water at concentrations of 3mM (8-
OHDPAT) and 1mM (WAY 100635), and stored at 20 C then
daily dissolved at desired experimental concentrations in aCSF.
Three experimental protocols were performed involving: 1)
5e10 min aCSF baseline, then 10min perfusion of 8-OH-DPAT fol-
lowed by 10e15min aCSF wash before applying WAY 100635 for
10 min, and 10 min of 8-OH-DPAT co-perfused with WAY 100635
(N ¼ 3 cells); 2) 5e10 min aCSF baseline, then 5e10 min perfusion
of 8-OH-DPAT followed by 5e10 min aCSF wash (N ¼ 11 cells); and
3) 5e10 min aCSF baseline, then 10 min perfusion of WAY 100635
followed by 10 min co-perfusion of WAY 100635 þ 8-OH-DPAT
(N ¼ 6 cells).
Firing rate of DTg neurons were calculated over 10-s bin in-
tervals for statistical analysis and for neuronal response histogram
representation of one responding DTg neuron in the complete
pharmacological protocol (1) (Fig. 5BeC, mean± S.E.M.). For anal-
ysis, we considered the mean baseline ﬁring frequency in aCSF
calculated over 2min prior to 5-HT1AR agonist application, and the
mean ﬁring rate during the maximum response to 8-OH-DPAT over
a duration of 2min. We calculated an averaged latency of
414± 42.5 s for 300 nM 8-OH-DPAT maximal response of DTg
neurons. Here, we only considered neurons that showed a response
to 8-OH-DPAT greater than baseline mean ﬁring rate ± 2 S.E.M.
(N¼ 10). To analyze the return to baseline values during the
washout, we calculated the mean ﬁring rate over a duration of
2min after 5min of aCSF wash. For the blocking protocol (3), we
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over 2min prior to 5-HT1AR antagonist, WAY 100635, application,
and the mean ﬁring rate calculated over the last 2 min under WAY
100635 before co-applying 8-OH-DPAT. We ﬁnally calculated the
average ﬁring rate over 2 min after 450 s of WAY 100635 þ 8-OH-
DPAT co-application (N ¼ 9). Other analysis were performed with
IgorPro 6.3 software (WaveMetrics, Portland, USA) using Patcher's
Power Tools, NeuroMatic plugins and Microsoft Excel software.
2.4.3. Whole-cell recordings
Cells were ﬁrst recorded in voltage-clamp mode at holding
potential of60mVwith a gain of 2mV/pA and low-pass ﬁltered at
2.9 kHz. Signals were sampled at 20 kHz. Passive membrane
properties and access resistance were extracted from current traces
recorded in response to a hyperpolarizing voltage pulse (200ms)
of 10mV from holding potential. The membrane resistance was
computed using the difference between the baseline current and
the current at 40ms during the voltage step. The integrated area
under the transient from the same trace was used to determine
membrane capacitance. Ten sweeps were averaged to remove
noise.
In current-clamp mode, spontaneous action potential activity
wasmonitored during 5min at 0 pA during aCSF perfusion from the
beginning of the recording. Signals were sampled at 10 kHz with a
gain of 2mV/pA. The detection and calculation of the ﬁring ratewas
done after 1min from the beginning of the recording during aCSF
baseline, over the rest of the recording (4min), and was identical as
above, using the appropriate template. To measure the membrane
potential, traces were ﬁltered off-line at 2 Hz, and the amplitude of
potential ﬂuctuations was averaged over the duration of the
recording. Series resistance was not compensated during the re-
cordings and membrane potential values were corrected off-line
with a liquid junction potential of 6.6mV. If access resistance
exceeded 30MU, the recording was discarded.
2.4.4. Biocytin visualization
After electrophysiological recordings, 15 neurons were injected
with biocytin (0.5%) added in the pipette internal solution to
conﬁrm their localization in the DTg. Slices containing one biocytin-
injected DTg cell were immersed in an ice-cold ﬁxative with 4%
paraformaldehyde in 0.01M phosphate-buffered saline (PBS) and
kept overnight at 4 C. After several washes in PBS, slices were
permeabilized in a 0.1% Triton X-100 (Sigma-Aldrich) solution
prepared in PBS (PBS-T) for 90min. Slices were incubated in
streptavidin-NL557 (1:2000 in PBS-T; NL999; R&D Systems) for 2 h
under stirring at room temperature in the dark. Sections were
rinsed 3 times in PBS during 10min and mounted between slide
and coverslip using Fluorsave mounting medium (Calbiochem).
Images were acquired on a Laser-Scanning Confocal System 228
(LSM 780; Zeiss, Oberkochen, Germany), mounted on an Axio
observer Z1 inverted microscope (Zeiss, Oberkochen, Germany).
HeeNe laser (543 nm) was used for excitation of Alexa Fluor 555,
and emission signals were ﬁltered. Images were acquired using Zen
2010 Software (Zeiss, Oberkochen, Germany) and processed in Fiji
software.
2.5. Anatomical procedures
2.5.1. Anatomical validation
After completion of the recordings, both lesions and injection
sites were checked. To do so, mice were deeply anesthetized:
lesioned mice were transcardially perfused (see below), whereas
animals that had been used for the pharmacological experiments
received 50 nl of pontamine sky blue dye (2%) through the
implanted cannula and were euthanized shortly after. Brains wereremoved and coronal brainstem sections were cut and Nissl
counterstained.
We delineated nuclear boundaries using the Nissl staining
(Kadar et al., 2009) to localize the DTg according to i) the in situ
hybridization labeling of 5-HT1AR mRNA (Fig. 1), ii) the anatomical
characterization of the DTg subnuclei performed by Hayakawa and
Zyo (1983), and iii) the mouse brain atlas (Franklin and Paxinos,
2008). The DTg is present on coronal brain sections extending
from ~ 5.00 to 5.6mm relative to bregma (Franklin and Paxinos,
2008). The 5-HT1AR mRNA labeling within the DTg extends from
~ 5.1 to 5.4mm relative to bregma, with highest signal density
at5.25mm (Fig. 1). The DTg lies in the central grey matter, ventral
to the 4th ventricle and dorsal to the medial longitudinal fasciculus,
medial to the laterodorsal tegmentum (LDTg) and lateral to the
caudal part of the DR. It is characterized by numerous stained
perikarya clustered in an oval shape bordered by an areawith fewer
stained cells. The caudal DR is delineated by the presence of some
large stained neurons located in the central greymatter, just ventral
to the 4th ventricle and dorsal to the medial longitudinal fasciculus
and medial to the left and right DTg.
The surface of DTg lesions was estimated as described by Bassett
et al. (2007) for the rat. Brieﬂy, brainstem sections were stained
with Nissl staining as described above to delineate nuclear
boundaries. The calculation of the lesioned surface was done for
each mouse, blind of the sleep results, by manual delimitation of
abnormal brain tissue, within counting boxes that encompassed
the DTg coordinates as deﬁned in the mouse brain atlas (Franklin
and Paxinos, 2008). We analyzed 6 sections of 20 mm thickness
per mouse, from 5.68 to 4.96mm relative to bregma and the
results were expressed in % of destruction of the DTg. Similar results
were obtained with NeuN immunostaining (Supplementary Fig. 1).
2.5.2. Tracer microinjections
Under K/X anesthesia, a glass micropipette (20e30 mm outside
tip diameter) ﬁlled with a solution (5%) of the anterograde tracer
Phaseolus vulgaris-leucoagglutinin (PHA-L, Vector, Burlingame, CA)
was lowered into the DTg [from bregma (Franklin and Paxinos,
2008): 5.3mm, AP, 0.25mm L, 2.95mmV] of adult male
C57Bl/6J mice (n¼ 7; 8-10 weeks-old, body weight: 23e26 g).
Iontophoretic application of PHA-L was made by passing positive
2e6 mA current pulses (20 s per 30 s period) for 10min. For retro-
grade tracing, iontophoretic injections of ﬂuorogold (FG, 2%; Mo-
lecular Probes®, Invitrogen, Carlsbad, CA) were targeted to the LM
[from bregma (Franklin and Paxinos, 2008): 2.4mm AP, 0.8mm L,
and 4.5/-4.75mmV] of adult male 5-HT1A-iCre/R26R mice (n¼ 5;
8-10 weeks-old, body weight: 23e26 g) using glass micropipettes
(25e40 mm outside tip diameter).
2.5.3. Viral tracing
Under K/X anesthesia, 400 nl of an adeno-associated (AAV1)
Cre-dependent helper virus carrying the green ﬂuorescent protein
(GFP), rabies glycoprotein (RG) and avian-speciﬁc retroviral re-
ceptor TVA [AAV-synP-FLEX-sTpEpB packaged by the University of
North Carolina vector core (Kohara et al., 2014),] was injected into
the LM [from bregma (Franklin and Paxinos, 2008): 2.4mm AP,
0.75mmL, and 4.75mmV] of VGLUT2-ires-cre mice (N¼ 4; 8-10
weeks-old male mice, body weight: 23e26 g). Ten days later, 500 nl
of rabies viruses encoding mCherry or GFP (SADDG GFP/mCherry;
generous gift of Prof. K.K. Conzelmann) were injected into the same
brain location. Brain tissue was removed and processed for dual in
situ hybridization one week after the rabies virus injection.
2.5.4. Histological procedures
Under deep pentobarbital anesthesia (150mg/kg i.p.), mice
were transcardially perfused with a ﬁxative solution of 4%
Fig. 1. 5-HT1AR are expressed by GABAergic neurons of the DTg. A. Coronal view at the level of the DTg adapted from the stereotaxic atlas of Franklin and Paxinos (2008). The grey
area corresponds to the DTg. B. High magniﬁcation image showing 5-HT1AR mRNA expression (revealed by X-Gal staining, blue dots) in the ventral part of the DTg in a Nissl-stained
coronal section of a 5-HT1A-iCre/R26R mouse. An example of 5-HT1AR expressing neurons is shown in 1 (and its two-fold magniﬁed 2) boxed area. C. Color photomicrograph of
the DTg with double labeling for 5-HT1AR (black grains) and GAD 67 (pink) mRNAs. Double labeled neurons are mainly observed in the ventral part of the DTg as shown in XI (and its
two-fold magniﬁed) 2 box area. Distance from bregma is indicated in mm (from Franklin and Paxinos, 2008). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this article.)
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Carlsbad, CA). The brains were removed and post-ﬁxed overnight.
Then, three series of 30 or 35 mm-thick coronal brain sections were
cut using a vibratome (VT-1000, Leica Microsystemes, Rueil-
Malmaison, France).
For b-galactosidase staining, one series of coronal sections were
incubated overnight in X-Gal solution (5mM potassium ferricya-
nide, 5mM ferrocyanide, 2mM MgCl2, 0.02% NP-40, 0.01% sodium
deoxycholate and 1mg/ml X-Gal) at 37 C. b-galactosidase activity
was visualized as blue dot staining in the cytoplasm of labeled cells.
All sections encompassing the DTg (N¼ 5) were visualized and
photomicrographs were captured from a representative section.
For immunohistological staining in tracing experiments, coronal
sections were incubated for 1 h in PBS containing 4% bovine serum
albumin (BSA) and 0.1% Triton X-100 (PBST). They were then
incubated overnight with either the goat polyclonal anti-PHA-L
antibody at 1:2000 (Vector) or the rabbit polyclonal anti-
ﬂuorogold antibody at 1:40,000 (Chemicon, Temecula, CA, USA)
in PBST. Secondary antibodies incubation (anti-goat or anti-rabbit
IgG at 1:200; Vector) followed by additional steps for 3,30-diaminobenzidine (DAB, Sigma) staining were performed as pre-
viously described (Bonnavion et al., 2010). Some sections were
double stained for PHA-L using nickel enhancement, followed by
immunostaining for histidine decarboxylase (HDC; rabbit anti-HDC
antiserum; 1:3,000, Acris Antibodies Gmbh, Herford, Germany)
without nickel, yielding black PHA-L ﬁbers and brown HDC-
immunoreactive cells. Stained sections were ﬁnally mounted on
gelatin-coated slides, dehydrated, and coverslipped with Eukitt
mounting medium (Kindler). Antibodies are described in
Supplementary Table 2. The anti-HDC antiserum was made in
rabbit against the rat enzyme. This anti-HDC antiserum stained C-
terminally truncated isoforms (54 and 63 kDa) and the full length
protein (73 kDa) in tissue homogenates from fetal rat liver (man-
ufacturer's technical information; Dartsch et al., 1998). The distri-
bution of HDC-positive neurons were in general agreement with
those previously described in the rat brain (Ericson et al., 1987).
Performance of the whole immunohistochemical procedure but
without HDC primary antibodies yielded sections with no immu-
nolabeling above background.
Dual in situ hybridization labeling for 5-HT1AR and GAD67
M. Chazalon et al. / Neuropharmacology 138 (2018) 315e330320(glutamate decarboxylase, 67 kDa type) mRNAs was performed as
described previously (Bonnavion et al., 2010). Dual ﬂuorescent in
situ hybridization (FISH) labeling for GAD67, VGLUT2 or the green
ﬂuorescent protein (GFP) mRNAs was performed as described in
Viereckel et al. (2016). Probes are described in Supplementary
Table 2.
For image acquisition, photomicrographs were captured on
different focal planes using a TRI CCD camera (JVC KY-F50; reso-
lution 576 768 pixels) connected to an Olympus BX21microscope
using a 40objective, andwere digitized by using a 3 8-bit color-
scale Openlab software (Improvision, Coventry, U.K.). The images
were then exported to Adobe Photoshop CS2 (version 9.0; Adobe
Systems,Mountain View, CA) tomount adjacent digitized images as
a ﬁnal large-ﬁeld high-resolution image and to adjust brightness
and contrast. For FISH and immunohistoﬂuorescence image
acquisition, sections were scanned on a NanoZoomer 2.0-HT
(Hamamatsu, Japan) at 20 resolution. Image microphotographs
were analyzed using the ndp2.view software (Hamamatsu, Japan).
For illustration purposes, the NanoZoomer imageswere exported in
Tiff format using NDP viewer. Images were then corrected for
contrast and cropped on Photoshop CS2.Fig. 2. Schematic drawings illustrating lesions of the DTg. A. Coronal view at the level of th
corresponds to the DTg. B-C. Representative photomicrographs of Nissl-stained brain section
DTg lesions (solid outlines) ordered from caudal (top) to rostral (down) DTg (Franklin and Pa
in mm (Franklin and Paxinos, 2008). (For interpretation of the references to color in this ﬁ2.6. Statistics
All data were analyzed using Prism 7.0 (GraphPad Software).
Statistical signiﬁcance was set at 0.05 for all procedures. Normality
and homoscedasticity assumptions were veriﬁed prior to the use of
any parametric tests (Shapiro-Wilk normality test and equality of
variances F-test). In case of violation of any of these assumptions,
standard transforms were applied to meet the above criteria. Sta-
tistics were performed with repeated measures two-way ANOVAs
to test the signiﬁcance between locus groups (“positive” or
“negative” sites, see Results) and pharmacological conditions (sa-
line or 8-OH-DPAT) for each time window (0e1 h, 1e2 h, 2e3 h)
and for each vigilance state (wake, NREM, REM), and between
lesion and time. These tests were followed by two-tailed unpaired
t-test with Welch's correction when necessary or non-parametric
Mann-Whitney tests between locus groups, lesioned and non-
lesioned control groups. Ratio paired t-test and non-parametric
two-tailed paired Wilcoxon test were also employed to assess the
signiﬁcance of the effects of pharmacological treatment on the
different variables (amounts of time spent in sleep/wake states,
latencies, bout mean durations, numbers of bouts). Statisticale DTg adapted from the stereotaxic atlas of Franklin and Paxinos (2008). The grey area
s from a sham-lesioned mouse (B) and a DTg lesioned mouse (C). D. Reconstructions of
xinos, 2008). Each color represents one mouse case. Distance from bregma is indicated
gure legend, the reader is referred to the Web version of this article.)
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the ﬁgures. Non-parametric Spearman correlation coefﬁcients were
calculated for comparing the extent of DTg lesions to sleep and
wake amounts.
For the data extracted from patch clamp electrophysiological
recordings, Friedman tests were performed to compare mean ﬁring
frequencies from aCSF, 8-OH-DPAT and aCSF wash conditions, and
from aCSF, WAY 100635 and WAY 100635 þ 8-OH-DPAT co-
perfusion conditions as described above, followed by Dunn's mul-
tiple comparisons tests. All data were expressed as mean ± S.E.M.3. Results
3.1. 5-HT1AR are expressed by GABAergic neurons in the DTg
We ﬁrst used 5-HT1A-iCre/R26R mice to precise further the
localization of 5-HT1AR-expressing cells that we previously iden-
tiﬁed in the DTg (Bonnavion et al., 2010, Fig. 1). In this transgenic
line, the mouse 5-HT1AR gene drives the expression of the Cre
recombinase that, in turn, activates the expression of b-Fig. 3. The effects of DTg bilateral lesion on sleep-wake patterns. A. Sleep-wake states acro
circles, N¼ 8) mice. The data are expressed as minutes per 2 h for the amounts of vigilance
during both the night and the light period in sham-lesioned (open bars, N¼ 7) and lesione
with the amount of wake (top, **P < 0.01), NREM sleep (middle, **P< 0.01), but not REM
means ± S.E.M. Mann Whitney tests were applied to assess the differences between sham a
amounts (ordinate) of each vigilance state and the extent of lesion (abscissa).galactosidase (Sahly et al., 2007). Analysis of b-galactosidase ac-
tivity, revealed by a speciﬁc blue labeling, showed that blue stained
neurons expressing 5-HT1AR are distributed preferentially in the
ventral part of the DTg (Fig. 1AeB) extending from5.1 to5.4mm
relative to bregma. At this caudo-rostral level, some stained neu-
rons are localized in the caudal part of the dorsal raphe nucleus
(DRc, Fig. 1B). In control conditions, R26R heterozygous mouse
brain sections showed no b-galactosidase staining (data not
shown). Dual ISH experiments were then performed to identify the
phenotype of 5-HT1AR mRNA expressing neurons in the DTg. We
found that GABAergic neurons labeled by the GAD67 riboprobe
(pink labeling) span the entire DTg (Fig. 1C). Co-localization with 5-
HT1AR mRNA hybridization signal was mainly observed in the
ventral part of the DTg, indicating the preferential location of 5-
HT1AR expressing GABAergic neurons in this DTg subarea (Fig. 1C).3.2. Electrolytic lesion of the DTg promotes wake
To assess the possible implication of the DTg in sleep regulation,
we ﬁrst examined the consequences of DTg lesions on sleep andss the light/dark cycle in sham-lesioned (open circles, N¼ 7) and lesioned (black ﬁlled
states. B. Amounts of wake, NREM sleep and REM sleep expressed as minutes per 12 h
d (black ﬁlled bars, N¼ 8)) mice. C. The extent (%) of the lesion correlates signiﬁcantly
sleep (bottom, P ¼ 0.09) during the light period (N ¼ 21). All data are expressed as
nd lesioned mice (*P< 0.05). Spearman correlation tests were performed between the
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M. Chazalon et al. / Neuropharmacology 138 (2018) 315e330 323wakefulness. Small intensity currents were delivered to make
bilateral lesions of the DTg in 14 mice. A representative example of
bilateral lesions is shown after Nissl (Fig. 2AeC) and NeuN
(Supplementary Fig. 1) staining. In six of these mice, DTg lesionwas
partial, with only 21± 7% of the nucleus destroyed, but in the
remaining 8 mice, extended lesionwas achieved with an average of
74± 6%. In three cases, the bilateral lesions extended to the midline
including the more caudal part of the DRc. For each mouse, the
extent of the lesion is illustrated in Fig. 2D. For these experiments,
the control group (N¼ 7) corresponded to sham-lesioned mice.
Mice with extended lesions (N ¼ 8) showed an increase in wake
amounts (þ31%; **P¼ 0.002; Fig. 3AeB) at the expense of NREM
sleep (13%; **P¼ 0.003; Fig. 3AeB) compared with sham-lesioned
mice (N ¼ 7) during the light period, but not during the dark active
period. As a result, the whole-day enhancement of wake amounts
in lesioned mice compared with sham-lesioned mice reached
only þ13% (data not shown). The limited amplitude of these
changes in wake amounts explains why they were not associated
with any signiﬁcant modiﬁcations of the number of wake episodes
or bout mean duration (Supplementary Table 3). On the other hand,
lesions of the DTg did not signiﬁcantly affect REM sleep amounts
despite a trend toward reduction (P¼ 0.08; Fig. 3AeB). To evaluate
whether the extent of lesion correlated with the increase inwake, a
regression analysis including all lesioned mice (N¼ 14) was per-
formed (Fig. 3C). A strong positive correlation was observed be-
tween the extent of the lesion and wake amounts during the light
period (r ¼ 0.63; **P ¼ 0.002). Conversely, NREM sleep amounts
negatively correlated with the extent of the lesion (r ¼ 0.66;
**P¼ 0.001). Finally, no correlation was found between DTg lesion
and REM sleep amounts during the light period (r¼ 0.38; P¼ 0.09).
Hence, these results showed that DTg lesions promoted wake
during the “resting” light period suggesting that DTg neuronsmight
be part of the network that modulates sleep-wake stages.
3.3. 5-HT1AR in the DTg modulate vigilance states
We next investigated the effect of microinjections of the 5-
HT1AR agonist 8-OH-DPAT into the DTg on vigilance states. Poly-
somnographic recordings were made in freely moving mice after
microinjection (ZT 3) of 8-OH-DPAT (250 pg, 50 nl) or saline (50 nl,
control) into the DTg (Fig. 4). On completion of the recordings,
histological inspection of the microinjection sites was performed
after local injection of pontamine sky blue dye. This allowed us to
distinguish two groups of mice (Fig. 4A) independently of the sleep
results. Injection sites within or at a distance of less than 200 mm
from the center of the DTg (at bregma 5.25mm as deﬁned by our
anatomical characterization of this nucleus in the Materials and
Methods) were considered as “positive” sites (N¼ 8; Fig. 4A). A
typical example of the pontamine sky blue staining obtained in a
“positive”mouse is illustrated in Supplementary Fig. 2A. “Negative”
sites corresponded to injection sites located at further rostro-
caudal levels and were considered as controls for locus speciﬁcity
(N¼ 9). The consequences of 8-OH-DPAT microinjections on vigi-
lance states were then analyzed in the two groups. In addition, toFig. 4. Activation of 5-HT1AR in the DTg enhances wake and reduces REM sleep. A. Schem
negative (n¼ 9, black triangles) injection sites were dyed with pontamine sky blue and rep
2008). Injection sites within or adjacent to the DTg are considered as positive sites. Negati
corresponds to the DTg nucleus. Each symbol represents the injection site in one mouse.
sequences of 8-OH-DPAT microinjections into the DTg on wake, NREM and REM sleep. Bars
during the ﬁrst 3 h of the recording period (N ¼ 8 “positive sites”, red circles; N ¼ 9 “neg
injections. Two-way repeated measures (RM) ANOVA between pharmacological conditions
hour of recording at the exception of REM sleep, where interaction is signiﬁcantly differe
**P < 0.01, F(1,15) ¼ 13.87; REM sleep 0e1 h: *P < 0.05 F(1,15) ¼ 6.94 and REM sleep 1e2 h::
conditions (*P < 0.05, **P< 0.01) and Mann-Whitney tests between locus groups (#P< 0.05, #
color in this ﬁgure legend, the reader is referred to the Web version of this article.)control the injection target of 8-OH-DPAT within the DTg, we
examined in two mice the labeling of [3H]8-OH-DPAT micro-
injected locally. We found that it covered bilaterally the entire DTg,
but also included the more caudal part of the DR (Supplementary
Fig. 3).
Microinjection of 8-OH-DPAT into “positive” sites within the
DTg disrupted sleep-wake pattern while it had no effect on sleep
architecture when performed into “negative” sites (Fig. 4B). In
“positive” sites, 8-OH-DPAT increased wake amounts during the
ﬁrst hour post-injection compared with saline microinjection
(þ42%; *P¼ 0.016, Fig. 4B WAKE). In parallel, NREM sleep (34%;
*P¼ 0.016, Fig. 4B NREM) and especially REM sleep (80%;
**P¼ 0.008, Fig. 4B REM) amounts were reduced. For the next two
following hours, wake (1e2 h: P¼ 0.25; and 2e3 h: P¼ 0.87) and
NREM sleep (1e2 h: P¼ 0.25; and 2e3 h: P> 0.99) amounts in 8-
OH-DPAT-microinjected mice returned to levels not signiﬁcantly
different from those recorded in saline-injected controls. However,
the effects of 8-OH-DPAT on the cumulative total amounts of time
of wake and NREM sleep over the ﬁrst 2 h remained signiﬁcant
(0e2 h: *P< 0.05; Supplementary Table 2). These effects were more
robust on the reduction of REM sleep amounts, which signiﬁcantly
persisted during the second hour post 8-OH-DPAT injection (1e2 h:
*P¼ 0.016; 0e2 h: ***P< 0.001; Supplementary Table 2). This REM
sleep inhibition induced by 8-OH-DPAT microinjection into the
“positive” sites resulted from a reduction in the number of REM
sleep bouts (Supplementary Table 3) and an increased latency for
the ﬁrst REM sleep episode to occur after treatment (23.6 ± 3.9 min
and 66.4 ± 13.4 min after intra-DTg microinjection of saline and 8-
OH-DPAT, respectively, Ratio paired t-test, **P ¼ 0.004;
26.4 ± 2.1 min and 66.4 ± 13.4 min in mice injected with 8-OH-
DPAT into “negative” and “positive” sites, respectively, Unpaired t-
test with Welch's correction, *P¼ 0.02). REM sleep amounts sub-
sequently returned to the control values observed with saline in-
jection during the third hour after 8-OH-DPAT microinjection into
“positive” sites (P¼ 0.71). A representative example of such modi-
ﬁcations is illustrated in the Supplementary Fig. 2B.
In contrast to the alterations in sleep-wake pattern in mice
injected into the “positive” sites, no signiﬁcant changes in wake
(P¼ 0.65), NREM sleep (P¼ 0.23) and REM sleep (P¼ 0.59) were
observed in mice injected with 8-OH-DPAT into the “negative” sites
(Fig. 4B), located more than 200 mm apart from DTg center. Alto-
gether, our data suggest that the activation of 5-HT1AR in the DTg
had a wake promoting inﬂuence at the expense of both NREM and
REM sleep, and strongly inhibited REM sleep.
3.4. GABAergic DTg neurons are inhibited by the activation of 5-
HT1AR
As 8-OH-DPAT displays afﬁnity for both 5-HT1AR and 5-HT7R, we
further assessed ex vivo the speciﬁc involvement of 5-HT1AR. We
performed patch-clamp recordings of DTg neurons in loose-seal
conﬁguration for minimal perturbation of their homeostasis in
response to 5-HT1AR agonist and antagonist (Fig. 5). Recorded
neurons conﬁned to the DTg (Fig. 5A) showed spontaneousatic drawings showing 8-OH-DPAT microinjection sites. Positive (n¼ 8, red dots) and
orted in atlas plates at seven different levels of the brainstem (Franklin and Paxinos,
ve sites are localized, at least, 200 mm apart from the center of the DTg. The grey area
Distance from bregma is indicated in mm (from Franklin and Paxinos, 2008). B. Con-
represent the amounts of the different vigilance states expressed as minutes per 1 h
ative sites”, black triangles) after saline (open bars) and 8-OH-DPAT (grey ﬁlled bars)
and locus groups showed a signiﬁcant interaction for each vigilance state on the ﬁrst
nt for the ﬁrst 2 h of recordings (WAKE: ***P < 0.001, F(1,15) ¼ 18.23; NREM sleep:
*P < 0.05 F(1,15) ¼ 7.43). These ANOVA were followed by Wilcoxon tests between drug
#P< 0.01). Data are expressed as means ± S.E.M. (For interpretation of the references to
Fig. 5. Inhibitory effects of 8-OH-DPAT on DTg neurons in a loose-seal patch conﬁguration. A. Localization of a recorded neuron in the DTg. Left: Photomicrograph showing a typical
mouse DTg slice containing one patched neuron ﬁlled with biocytin (0.5%), revealed with streptavidin-NL557 nm. Right: Magniﬁcation of the framed region showing the patched
neuron. B. Mean ﬁring rates from a recording of a responding DTg neuron: a) during aCSF baseline, b) during the 8-OH-DPAT perfusion (300 nM), c) at the end of the aCSF wash, d)
during aCSF second baseline, e) during perfusion of the selective 5-HT1A antagonist, WAY 100635 (1 mM), and f) during the co-perfusion with 8-OH-DPAT (300 nM). Each histogram
bar represents mean ﬁring rate calculated over 10-s bin interval± S.E.M. The arrow and asterisk represent the re-positioning of the micropipette to maintain a proper loose-seal
leading to a mechanical excitation of the cell (aCSF baseline 2 in d). C. Extracellular action potentials taken from position a-f in B. D-E. Population graph summaries showing: (D) the
inhibitory effects of bath-applied 8-OH-DPAT (300 nM) on the ﬁring rate of DTg neurons (N¼ 10), and (E) selective prevention of 8-OH-DPAT mediated response by WAY 100635
(1 mM) in another set of DTg neurons (N¼ 9). Grey circles connected by lines represent values for individual neurons. Group means± S.E.M are represented by the black lines for
each condition. Non-parametric ANOVA Friedman tests were performed (D: **P< 0.01, E: P ¼ 0.28) followed by Dunn's multiple comparisons tests illustrated in the graphs:
**P < 0.01, *P< 0.05, n.s. not signiﬁcant P> 0.05.
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(N¼ 23) during baseline aCSF recordings. In another series of
patch-clamp recordings, we recorded DTg neurons in whole-cell
conﬁguration to extract their passive and active membrane prop-
erties (see Supplementary Fig. 4).
We tested the effects of 8-OH-DPAT (300 nM) on 14 neurons.We
found that 10/14 neurons were progressively inhibited by 8-OH-
DPAT (Fig. 5BeD) resulting in a signiﬁcant decrease in their mean
ﬁring frequency (Friedman test **P< 0.01) from 9.6± 0.7 Hz at aCSF
baseline (taken over 2min before 5-HT1A agonist application), to6.1± 1.1 Hz at their maximal response to 8-OH-DPAT (**P< 0.01). As
shown in Fig. 5BeC(a,b,c) and Fig. 5E, this action of 8-OH-DPAT was
fully reversed by aCSF washout (*P< 0.05), with the ﬁring rate back
to a value (9.3± 0.8 Hz) not signiﬁcantly different from baseline
(P> 0.99). These neurons were individually selected based on a
signiﬁcant variation greater than baseline mean ﬁring frequency ±
2 S.E.M. in response to 8-OH-DPAT. The spontaneous ﬁring ac-
tivity of the four remaining neurons was not signiﬁcantly affected
by 8-OH-DPAT application (Friedman test P¼ 0.43; aCSF baseline:
7.9± 2Hz, 8-OH-DPAT: 8.1± 2.1 Hz, aCSF wash: 7.5± 1.4 Hz). Thus,
Fig. 6. 5-HT1AR expressing neurons of the DTg mainly target non histaminergic neurons in the LM. A. Anterograde tracing from the DTg. A1. Photomicrograph of PHA-L injection site
(brown staining) located in the DTg. A2. Drawings illustrating the extent of PHA-L labeled axons and terminals innervating the LM. This series of coronal section drawings
correspond roughly, from caudal to rostral, to Bregma levels 2.9 to 2.7mm (Franklin and Paxinos, 2008). The framed region corresponds to the photomicrograph in A3. A3.
Photomicrograph showing PHA-L labeled axons and terminal boutons originating from the DTg (black staining) and histaminergic neurons immunostained for histidine decar-
boxylase (brown cytoplasmic neurons) in the LM. B. Retrograde tracing from the LM. B1. Coronal section at the level of the LM adapted from the stereotaxic atlas of Franklin and
Paxinos (2008). The framed region in B1 corresponds to the photomicrograph in B2. B2. Photomicrograph of Fluorogold injection site (brown staining) located in the LM. B3.
Retrogradely labeled neurons (brown staining) were seen in the ventral part of the DTg. The framed region in B3 corresponds to the photomicrograph in B4. B4. Photomicrograph of
5-HT1AR expressing neurons (blue staining) retrolabeled for Fluorogold (brown staining) in the ventral part of the DTg. Distance from bregma is indicated in mm (Franklin and
Paxinos, 2008). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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inhibited by 8-OH-DPAT.
To further conﬁrm the selective involvement of 5-HT1AR, we
pre-applied WAY 100635 followed byWAY 100635 (1 mM)þ 8-OH-DPAT (300 nM) co-perfusion on DTg slices (Fig. 5BeC, E). On 9/9
neurons, the pre-application of WAY 100635 (1 mM) prevented the
8-OH-DPAT inhibition of ﬁring without modifying the group
baseline mean ﬁring rate (Friedman test P¼ 0.28; aCSF baseline:
Fig. 7. Synaptic inputs to glutamatergic (VGLUT2) neurons in the LM using cell-type speciﬁc rabies virus-based monosynaptic tracing in VGLUT2-ires-cre mice. A. Identiﬁcation of
the infected neurons in the LM of VGLUT2-ires-cre mice. A1: Coronal view at the level of the LM (grey area) adapted from the stereotaxic atlas of Franklin and Paxinos (2008). A2.
Selective expression of GFP mRNA (green) corresponding to infected cells (top), and of VGLUT2 mRNA (red) corresponding to glutamatergic neurons (middle). The merged image
(bottom) shows selective expression of GFP in glutamate VGLUT2 neurons of the LM (yellow, expressing both GFP and VGLUT2). B. Identiﬁcation of the retrogradely labeled neurons
in the DTg. B1: Coronal view at the level of the DTg (grey area) adapted from the stereotaxic atlas of Franklin and Paxinos (2008). B2. High magniﬁcation superimposed image of GFP
(green) and GAD67 (red) mRNA expression in the DTg area after monosynaptic viral tracing in VGLUT2-ires-cre mice. Yellow cells correspond to neurons expressing both GFP and
GAD67 mRNAs. B3. Magniﬁcation of the framed region in B2 showing selective expression of GFP (green) corresponding to retrogradely labeled neurons (top), and of GAD67 (red)
corresponding to GABAergic neurons (middle). The merged image (bottom) shows selective expression of GFP in GABAergic neurons of the ventral part of the DTg (yellow,
expressing both GFP and GAD67). Distance from bregma is indicated in mm (Franklin and Paxinos, 2008). (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this article.)
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8.8 ± 1.2 Hz; Fig. 5BeC(d,e,f), E). However, looking at individual
responses, we noticed that the application of WAY 100635 in two
cells increased ﬁring rate from baseline values (N¼ 2/9). In one cell
the opposite effect of WAY 100635 application was observed
(N¼ 1/9), whereas the ﬁring activity of the majority of recorded
DTg neurons remains unaffected by WAY 100635 application
(N¼ 6/9). These individual responses indicate that certain DTg cells
exhibit some variability in their ﬁring rate and/or there may be an
endogenous 5-HT tone on which WAY 100635 had an effect.
However, collectively, these ex vivo recordings showed that the
agonist 8-OH-PAT inhibits the activity of DTg neurons by specif-
ically acting on 5-HT1AR.
3.5. GABAergic DTg neurons exclusively target glutamatergic
neurons of the caudal hypothalamus
To identify the anatomical targets of DTg neurons, anterograde
tracing experiments were performed in C57Bl/6J mice (Fig. 6A).
PHA-L tracer was injected into the DTg (Fig. 6A1). Similarly to what
had been found in other mammal species (Hayakawa and Zyo,
1984), a dense terminal labeling appeared ipsilaterally in the
lateral mammillary nucleus (LM) of the mammillary bodies
throughout its caudo-rostral extension in the mouse brain
(Fig. 6A2). The rest of the brain was completely devoid of PHA-L
labeling showing that DTg neurons project exclusively to the LM.
Because histaminergic neurons of the tuberomammillary nucleus
(TMN), which forms a shell around the ventral parts of the
mammillary bodies (Panula et al., 1984), are known to play a key
role in wake maintenance (Takahashi et al., 2006), we examined
whether neurons of the DTg could directly contact them. Double
immunostaining was then performed to visualize PHA-L immu-
noreactive ﬁbers and HDC immunoreactive cell bodies. As shown in
Fig. 6A3, PHA-L labeled terminals from the DTg were seen in close
proximity to HDC immunoreactive histaminergic neurons. How-
ever, appositions between PHA-L labeled ﬁbers and HDC-
immunolabeled neurons were only rarely visualized, indicating
that DTg neurons target mainly neurons of an unknown phenotype
in close proximity to histaminergic neurons.
Projection from the DTg to the LM was further conﬁrmed by
using the Fluorogold retrograde tracer injected into the LM of 5-
HT1A-iCre/R26R mice (Fig. 6B). In these mice, all the cells that
have an active promoter of the 5-HT1AR gene can be visualized with
a highly sensitive X-Gal staining (Sahly et al., 2007). A Fluorogold
injection targeting the LM is shown in Fig. 6B1-B2. A large number
of retrogradely labeled neurons was found ipsilaterally in the
ventral part of the DTg (Fig. 6B3-B4). They nearly all expressed the
5-HT1AR as evidenced by blue dots present in the cytoplasm of
Fluorogold immunoreactive neurons stained in brown (Fig. 6B4).
In addition to histaminergic neurons, the LM contains a high
number of VGLUT2-positive neurons as revealed by FISH labeling
(Fig. 7A). We next asked whether LM glutamatergic (VGLUT2)
neurons may be a critical target for DTg GABAergic neurons. To test
this hypothesis, we mapped inputs to VGLUT2 neurons of the LM
using monosynaptic rabies tracing (Kohara et al., 2014). Rabies vi-
rus and cre-dependent helper AAV were microinjected into the LM
of VGLUT2-ires-cre mice to selectively target VGLUT2 neurons. To
examine the cell-type-speciﬁcity of the infected neurons and the
phenotype of retrogradely labeled neurons, we performed mRNA-
selective dual FISH. Probes towards VGLUT2 and GFP mRNAs
were included for detection of the infected neurons in the LM
(Fig. 7A), and GAD67 and GFP mRNAs for detection of retrogradelly
labeled neurons in the DTg (Fig. 7B). Dual FISH in the LM showed
that all GFP positive neurons express VGLUT2 mRNA conﬁrming
that all infected neurons are glutamatergic VGLUT2 neurons(Fig. 7A2). As shown in Fig. 7B, retrogradely labeled neurons as
revealed by GFP expression are exclusively found in the ventral part
of the DTg. Importantly, these neurons are GABAergic as shown by
the perfect co-localization of GFP and GAD67 mRNA labeling
(Fig. 7B2-3). This retrograde mapping showed that LM gluta-
matergic VGLUT2 neurons receive direct inputs from GABAergic
neurons of the ventral DTg.
Altogether, this anatomical study revealed that 5-HT1AR
expressing GABAergic neurons in the ventral DTg exclusively target
glutamatergicVGLUT2, but not histaminergic, neurons in the LM.
4. Discussion
In this study, we show that the DTg, a brainstem GABAergic
nucleus expressing high levels of 5-HT1AR, is involved in the
regulation of wakefulness. Previous electrophysiological, pharma-
cological and genetic studies had evidenced a role for 5-HT neurons
in promoting wake and inhibiting REM sleep (McGinty and Harper,
1976; Rasmussen et al., 1984; Sakai, 2011). Although numerous
reports had addressed the possibility that 5-HT1AR could mediate
the inﬂuence of 5-HT on sleep, the speciﬁc structures where they
would play such a role had not been identiﬁed. Here, we show that
one of these structures is the DTg. Indeed, lesion of the DTg pro-
motes wake andmicroinjection of the prototypical 5-HT1AR agonist
8-OH-DPAT into this nucleus promotes wake and inhibits REM
sleep. Finally, we identify glutamatergic neurons of the hypotha-
lamic LM as the exclusive target of DTg neurons. Overall, these re-
sults suggest that 5-HT promotes wake by exerting an inhibitory
control mediated by 5-HT1AR on GABAergic DTg neurons projecting
to the LM.
4.1. The DTg as a key structure in 5-HT-mediated wake/sleep
regulation
The principal goal of our study was to assess the inﬂuence of the
DTg on vigilance states in connectionwith the 5-HT system.We had
previously identiﬁed this nucleus as being essentially GABAergic
(Bonnavion et al., 2010). We now report that local activation of the
5-HT1AR in this nucleus enhances wake and reduces REM sleep,
which mimics the effects observed after the systemic administra-
tion of the agonist 8-OH-DPAT (Portas and Grønli, 2008). Thewake-
promoting effects are also recapitulated by DTg lesions. However,
REM sleep inhibition is only observed after acute pharmacological
inactivation of the DTg and not after its lesion. Such discrepancy
might be accounted for by compensatory mechanisms triggered by
the lesion, as sleep was recorded at least 2 weeks away from the
lesionning procedure.
Besides, because the DTg is composed of extremely small
bilateral nuclei, lesions or 8-OH-DPAT microinjections might have
impacted adjacent regions. Indeed, the agonist could spread away
from the injection site (see Supplementary Fig. 2) and thus reach
the caudal part of the dorsal raphe nucleus (DRN) that comprises
somatodendritic 5-HT1A autoreceptors on 5-HT neurons. While we
cannot rule out a possible involvement of the latter nucleus in our
sleep analysis convergent data are not in support of the implication
of somatodendritic 5-HT1A autoreceptors on 5-HT neurons in the
DR but rather favor the idea of the speciﬁc involvement of 5-HT1AR
on DTg neurons. In particular, 1) injections of 8-OH-DPAT caudally
or rostrally to the DTg (more than 200 mm apart from the nucleus)
had no effect onwake/sleep parameters (Fig. 2) and 2) activation of
5-HT1A autoreceptors in the DRN results in an increase (Portas et al.,
1996; Bjorvatn et al., 1997) or no change (Sakai and Crochet, 2001)
of REM sleep, and 3) large lesions of the 5-HT cells in the DR do not
modify the sleep/wake cycle in rats (Tissier et al., 1993). Therefore,
it can be reasonably concluded that the 5-HT1AR within the DTg
M. Chazalon et al. / Neuropharmacology 138 (2018) 315e330328actually mediate the 8-OH-DPAT-induced wake enhancement and
REM sleep inhibition. Overall, both the electrolytic lesion of the DTg
and its pharmacological inactivation (through inhibitory 5-HT1AR)
produced a common effect, i.e. wake promotion, thus validating
further the involvement of the DTg in sleep/wake regulation.
As 8-OH-DPAT acts on both 5-HT1AR and 5-HT7R, we therefore
addressed the speciﬁc involvement of 5-HT1AR ex vivo on brain
slices including the DTg. We found that the vast majority of DTg
neuronswere inhibited by 8-OH-DPAT, an effect that was prevented
by the application of the selective 5-HT1AR antagonist, WAY
100635. Additionally, we investigated the presence of 5-HT7R in the
DTg using dual FISH, and found that 5-HT7R expressing neurons are
barely present in the mouse DTg in comparison to LDTg/para-
brachial region (Supplementary Fig. 5). Altogether, these results
brought further evidences that 5-HT exerts an inhibitory control
over GABAergic neurons of the DTg impacting sleep/wake states.
4.2. The ACh-5-HT hypothesis of sleep-wake regulation revisited
Up to now, 5-HT inhibition of REM sleep was proposed to rely on
a reciprocal inhibition between REM sleep active (REM-on)
cholinergic neurons of the pedunculopontine and laterodorsal
tegmentum (PPTg/LDTg) nuclei on the one hand, and mono-
aminergic REM sleep inactive (REM-off) neurons on the other hand
(Hobson et al., 1975). Support to this theory notably includes in vitro
and in vivo electrophysiological data showing that 5-HT inhibits the
activity of cholinergic LDTg/PPTg neurons via 5-HT1AR activation in
rats (Luebke et al., 1992), cats (Thakkar et al., 1998) and guinea pigs
(Leonard and Llinas, 1994). However, local microinjection of 5-
HT1AR agonists into the LDTg/PPTg was reported to either inhibit
REM sleep without affecting wake (Horner et al., 1997; Monti and
Jantos, 2003) or exert no effect on sleep (Sanford et al., 1996;
Datta et al., 2003; Grace et al., 2012). These contradictory ﬁndings
have been attributed to anatomical differences between species, to
the speciﬁcity of different ligands used or to age differences.
However, none of these studies controlled for the ligand diffusion,
deﬁned the anatomical region involved, or investigated for the
presence of 5-HT1AR in the LDTg/PPTg nuclei. In light of our present
data, these points might be critical issues because the DTg, which
contains high density of 5-HT1AR, lies just next to the LDTg and thus
could have been the actual target for 8-OH-DPAT to trigger its ef-
fects on sleep. In addition, we demonstrated previously that 5-
HT1AR are not expressed by cholinergic neurons in the LDTg
(Bonnavion et al., 2010). Altogether, our data would support the
idea that the GABAergic neurons of the DTg, but not the cholinergic
ones in the LDTg/PPTg, mediate 5-HT facilitation of wake. This
inference is in line with recent reports asserting the role of
GABAergic neurons in the brainstem and in the medulla in sleep/
wake regulations (Boissard et al., 2003; Lu et al., 2006; Anaclet
et al., 2014; Hayashi et al., 2015; Weber et al., 2015; Cox et al.,
2016). Accordingly, we propose that GABAergic DTg neurons,
which are under an inhibitory control driven by 5-HT wake-on
neurons, participate to sleep/wake regulatory loops
(Supplementary Fig. 6).
4.3. A new role for the Gudden's nucleus?
To date, the sole known function attributed to the DTg is to
generate the head direction cell (HD) signal (Sharp et al., 2001;
Bassett et al., 2007). HD cells encode the animal's head direction in
the horizontal plane and are thus critical for navigation (see Taube,
2007 for review). They are mainly found within serially connected
structures belonging to the Papez's circuit including the LM, the
anterior dorsal thalamic nucleus, the postsubiculum, the retro-
splenial cortex and the medial enthorhinal cortex. Actually, DTgneurons have reciprocal connections with the LM (Supplementary
Fig. 6), a ﬁnding that is remarkably conserved across mammalian
species (Hayakawa and Zyo, 1984; Shibata, 1987; Wirtshafter and
Stratford, 1993; Saunders et al., 2012). Our results from both
anterograde and retrograde tracing further show that neurons of
the ventral part of the DTg exclusively innervate the glutamatergic
cells of the LM in the mouse brain. Here, we propose an additional
role for the DTg/LM pathway in sleep-wake behavior, in line with
a recent report showing that neuronal activity in the HD system is
closely dependent on sleep-wake states (Peyrache et al., 2015).
Nevertheless, further studies will be necessary to determine
whether DTg neurons exhibit a state-related activity pattern to
strengthen its role in regulating sleep/wake stages.
The existence of a functional connection between the 5-HT
system and the DTg is strongly supported by anatomical ﬁndings.
Thus, the DTg contains a remarkably dense 5-HT terminal inner-
vation issued from the median raphe nucleus (MRN; Bang et al.,
2012; Muzerelle et al., 2016) and we found that virtually all DTg
neurons projecting to the LM express 5-HT1AR (Bonnavion et al.,
2010). These ﬁndings allow us to describe a novel network
through which 5-HT neurons can sustain wake. In this network,
inhibition of GABAergic DTg neurons by 5-HT MRN neurons
through Gi-coupled 5-HT1AR activation would disinhibit gluta-
matergic LM neurons that, in turn, would facilitate wake occur-
rence (Supplementary Fig. 6). This model implies that
glutamatergic LM neurons in the posterior hypothalamus can
promote wake. Indeed the posterior hypothalamus, classically
deﬁned as a waking center (Sakai et al., 1990; Lin, 2000), contains
wake-speciﬁc neurons that are active only during waking, evi-
denced by extracellular unit recordings in cats (Vanni-Mercier
et al., 2003), rats (Steininger et al., 1999) and mice (Takahashi
et al., 2006). Most of these wake-speciﬁc neurons have been
identiﬁed by juxta-cellular labeling as histaminergic neurons in the
TMN (Takahashi et al., 2006), adjacent to the LM. However, we
found here that terminals from the DTg only rarely contact hista-
minergic neurons in the LM. Alternatively, non-histaminergic
wake-active neurons have also been described in the posterior
hypothalamus, within and surrounding the TMN/LM area (Vanni-
Mercier et al., 2003; Takahashi et al., 2006), including gluta-
matergic cells (Pedersen et al., 2017), which therefore could be the
target of GABAergic DTg neurons to modulate wakefulness.
Further investigations will be required to establish the causal
role of the DTg and its connection with the LM in sleep-wake
regulation. Here, our approaches including electrolytic lesions of
the DTg have clear limitations due to the destruction of both somas
and ﬁbers of passage, which weaken the speciﬁc role we attributed
to the DTg. These limitations can be overcome thanks to the use of
chemo- or opto-genetic tools. Our ﬁndings by revealing that the
glutamatergic LM is the exclusive target of the GABAergic DTg offer
a unique opportunity for conditional expression of these engi-
neered receptors through LM retrograde tracing.5. Conclusion
This study provides the ﬁrst evidence that the GABAergic DTg is
a target for 5-HT regulation of sleep and wakefulness highlighting a
new ponto-hypothalamic pathway through which 5-HT facilitates
wakefulness (Supplementary Fig. 6). This pathway includes long-
range projecting GABAergic neurons of the ventral part of the DTg
that exclusively target glutamatergic neurons of the LM and receive
inhibitory inputs from the MRN. We propose that 5-HT MRN neu-
rons exert an inhibitory control on this DTg/LM pathway to
modulate sleep-wake states bringing to light a new function of the
DTg in the sleep-wake networks.
M. Chazalon et al. / Neuropharmacology 138 (2018) 315e330 329Funding and disclosure
This research was supported by Institut National de la Sante et
de la Recherche Medicale, and Universite Pierre et Marie Curie.
During performance of this work, PB was supported by the Minis-
tere de la Recherche et de la Technologie (MRT), the Fondation pour
la Recherche Medicale and the European Marie Sklodowska-Curie
Actions. The authors declare no conﬂict of interest.
Author's contributions
VF and PB equally contributed to this work. PB, JFB, MH, JA and
VF designed and analyzed the studies. MC and PB performed and
analyzed the electrophysiological patch clamp recordings. SD, AKE
and PB performed and analyzed the monosynaptic tracing experi-
ments. SD, JFB, PB and VF performed and analyzed all the
anatomical studies. SD designed and validated the cRNA probes and
FISH protocols. IS and FT provided the transgenic 5-HT1A-iCre/R26R
mice. All authors contributed to ﬁnalize the manuscript for sub-
mission for publication.
Acknowledgements
We dedicate this article to the memory of Dr. Jean-François
Bernard, an exceptional scientist, wonderful supporter, and
devoted friend. We would like to thank Pr. Karl-Klaus Conzelmann
and Dr. Alexander Ghanem for their generous gift of the rabies vi-
rus, and Dr. Christophe Varin for valuable comments on the
manuscript and analysis.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.neuropharm.2018.06.014.
References
Anaclet, C., Ferrari, L., Arrigoni, E., Bass, C.E., Saper, C.B., Lu, J., et al., 2014. The
GABAergic parafacial zone is a medullary slow wave sleep-promoting center.
Nat. Neurosci. 17 (9), 1217e1224.
Bang, S.J., Jensen, P., Dymecki, S.M., Commons, K.G., 2012. Projections and in-
terconnections of genetically deﬁned serotonin neurons in mice. Eur. J. Neu-
rosci. 35 (1), 85e96.
Bassett, J.P., Tullman, M.L., Taube, J.S., 2007. Lesions of the tegmentomammillary
circuit in the head direction system disrupt the head direction signal in the
anterior thalamus. J. Neurosci. 27 (28), 7564e7577.
Bjorvatn, B., Fagerland, S., Eid, T., Ursin, R., 1997. Sleep/waking effects of a selective
5-HT1A receptor agonist given systemically as well as perfused in the dorsal
raphe nucleus in rats. Brain Res. 770 (1e2), 81e88.
Boissard, R., Fort, P., Gervasoni, D., Barbagli, B., Luppi, P.H., 2003. Localization of the
GABAergic and non-GABAergic neurons projecting to the sublaterodorsal nu-
cleus and potentially gating paradoxical sleep onset. Eur. J. Neurosci. 18 (6),
1627e1639.
Bonnavion, P., Bernard, J.F., Hamon, M., Adrien, J., Fabre, V., 2010. Heterogeneous
distribution of the serotonin 5-HT(1A) receptor mRNA in chemically identiﬁed
neurons of the mouse rostral brainstem: implications for the role of serotonin
in the regulation of wakefulness and REM sleep. J. Comp. Neurol. 518 (14),
2744e2770.
Boutrel, B., Monaca, C., Hen, R., Hamon, M., Adrien, J., 2002. Involvement of 5-HT1A
receptors in homeostatic and stress-induced adaptive regulations of paradox-
ical sleep: studies in 5-HT1A knock-out mice. J. Neurosci. 22 (11), 4686e4692.
Cox, J., Pinto, L., Dan, Y., 2016. Calcium imaging of sleep-wake related neuronal
activity in the dorsal pons. Nat. Commun. 7, 10763.
Datta, S., Mavanji, V., Patterson, E.H., Ulloor, J., 2003. Regulation of rapid eye
movement sleep in the freely moving rat: local microinjection of serotonin,
norepinephrine, and adenosine into the brainstem. Sleep 26 (5), 513e520.
Dartsch, C., Chen, D., Persson, L., 1998. Multiple forms of rat stomach histidine
decarboxylase may reﬂect posttranslational activation of the enzyme. Regul.
Pept. 77 (1e3), 33e41.
Ericson, H., Watanabe, J., K€ohler, C.H., 1987. Morphological analysis of the tuber-
omammillary nucleus in the rat brain: delineation of subgroups with antibody
against l-histidine decarboxylase as a marker. J. Comp. Neurol. 263 (1), 1e24.
Franklin, K.B.J., Paxinos, G., 2008. The Mouse Brain in Stereotaxic Coordinates.Academic Press, San Diego.
Grace, K.P., Liu, H., Horner, R.L., 2012. 5-HT1A receptor-responsive pedunculopontine
tegmental neurons suppress REM sleep and respiratory motor activity.
J. Neurosci. 32 (5), 1622e1633.
Hasegawa, E., Maejima, T., Yoshida, T., Masseck, O.A., Herlitze, S., Yoshioka, M., et al.,
2017. Serotonin neurons in the dorsal raphe mediate the anticataplectic action
of orexin neurons by reducing amygdala activity. Proc. Natl. Acad. Sci. U. S. A.
114 (17), E3526eE3535.
Hayakawa, T., Zyo, K., 1983. Comparative cytoarchitectonic study of Gudden's
tegmental nuclei in some mammals. J. Comp. Neurol. 216 (3), 233e244.
Hayakawa, T., Zyo, K., 1984. Comparative anatomical study of the tegmento-
mammillary projections in some mammals: a horseradish peroxidase study.
Brain Res. 300 (2), 335e349.
Hayashi, Y., Kashiwagi, M., Yasuda, K., Ando, R., Kanuka, M., Sakai, K., et al., 2015.
Cells of a common developmental origin regulate REM/non-REM sleep and
wakefulness in mice. Science 350 (6263), 957e961.
Hobson, J.A., McCarley, R.W., Wyzinski, P.W., 1975. Sleep cycle oscillation: reciprocal
discharge by two brainstem neuronal groups. Science 189 (4196), 55e58.
Horner, R.L., Sanford, L.D., Annis, D., Pack, A.I., Morrison, A.R., 1997. Serotonin at the
laterodorsal tegmental nucleus suppresses rapid-eye-movement sleep in freely
behaving rats. J. Neurosci. 17 (19), 7541e7552.
Jouvet, M., 1962. Research on the neural structures and responsible mechanisms in
different phases of physiological sleep. Arch. Ital. Biol. 100, 125e206.
Kadar, A., Wittmann, G., Liposits, Z., Fekete, C., 2009. Improved method for com-
bination of immunocytochemistry and Nissl staining. J. Neurosci. Meth. 184,
115e118.
Kia, H.K., Miquel, M.C., Brisorgueil, M.J., Daval, G., Riad, M., El Mestikawy, S., et al.,
1996. Immunocytochemical localization of serotonin1A receptors in the rat
central nervous system. J. Comp. Neurol. 365 (2), 289e305.
Kohara, K., Pignatelli, M., Rivest, A.J., Jung, H.Y., Kitamura, T., Suh, J., Frank, D.,
Kajikawa, K., Mise, N., Obata, Y., Wickersham, I.R., Tonegawa, S., 2014. Cell type-
speciﬁc genetic and optogenetic tools reveal hippocampal CA2 circuits. Nat.
Neurosci. 17, 269e279.
Leonard, C.S., Llinas, R., 1994. Serotonergic and cholinergic inhibition of meso-
pontine cholinergic neurons controlling REM sleep: an in vitro electrophysio-
logical study. Neuroscience 59 (2), 309e330.
Lin, J.S., 2000. Brain structures and mechanisms involved in the control of cortical
activation and wakefulness, with emphasis on the posterior hypothalamus and
histaminergic neurons. Sleep Med. Rev. 4 (5), 471e503.
Loucif, A.J.C., Bonnavion, P., Macri, B., Golmard, J.L., Boni, C., Melfort, M., Leonard, G.,
Lesch, K.P., Adrien, J., Jacquin, T.D., 2006. Gender-dependent regulation of G-
protein-gated inwardly rectifying potassium current in dorsal raphe neurons in
knock-out mice devoid of the 5-hydroxytryptamine transporter. J. Neurobiol.
66, 1475e1488.
Lu, J., Sherman, D., Devor, M., Saper, C.B., 2006. A putative ﬂip-ﬂop switch for
control of REM sleep. Nature 441 (7093), 589e594.
Luebke, J.I., Greene, R.W., Semba, K., Kamondi, A., McCarley, R.W., Reiner, P.B., 1992.
Serotonin hyperpolarizes cholinergic low-threshold burst neurons in the rat
laterodorsal tegmental nucleus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89 (2),
743e747.
Maudhuit, C., Jolas, T., Lainey, E., Hamon, M., Adrien, J., 1994. Effects of acute and
chronic treatment with amoxapine and cericlamine on the sleep-wakefulness
cycle in the rat. Neuropharmacology 33 (8), 1017e1025.
McGinty, D.J., Harper, R.M., 1976. Dorsal raphe neurons: depression of ﬁring during
sleep in cats. Brain Res. 101 (3), 569e575.
Mebatsion, T., Konig, M., Conzelmann, K.K., 1996. Budding of rabies virus particles in
the absence of the spike glycoprotein. Cell 84, 941e951.
Monaca, C., Boutrel, B., Hen, R., Hamon, M., Adrien, J., 2003. 5-HT1A/1B receptor-
mediated effects of the selective serotonin reuptake inhibitor, citalopram, on
sleep: studies in 5-HT1A and 5-HT1B knockout mice. Neuropsychopharmacology
28 (5), 850e856.
Monti, J.M., Jantos, H., 2003. Differential effects of the 5-HT1A receptor agonist
ﬂesinoxan given locally or systemically on REM sleep in the rat. Eur. J. Phar-
macol. 478 (2e3), 121e130.
Muzerelle, A., Scotto-Lomassese, S., Bernard, J.F., Soiza-Reilly, M., Gaspar, P., 2016.
Conditional anterograde tracing reveals distinct targeting of individual sero-
tonin cell groups (B5-B9) to the forebrain and brainstem. Brain Struct. Funct.
221 (1), 535e561.
Panula, P., Yang, H.Y., Costa, E., 1984. Histamine-containing neurons in the rat hy-
pothalamus. Proc. Natl. Acad. Sci. U. S. A. 81 (8), 2572e2576.
Pedersen, N.P., Ferrari, L., Venner, A., Wang, J.L., Abbott, S.B.G., Vujovic, N.,
Arrigoni, E., Saper, C.B., Fuller, P.M., 2017. Supramammillary glutamate neurons
are a key node of the arousal system. Nat. Commun. 8.
Peyrache, A., Lacroix, M.M., Petersen, P.C., Buzsaki, G., 2015. Internally organized
mechanisms of the head direction sense. Nat. Neurosci. 18 (4), 569e575.
Portas, C.M., Thakkar, M., Rainnie, D., McCarley, R.W., 1996. Microdialysis perfusion
of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the dorsal raphe
nucleus decreases serotonin release and increases rapid eye movement sleep in
the freely moving cat. J. Neurosci. 16 (8), 2820e2828.
Portas, C.M., Bjorvatn, B., Ursin, R., 2000. Serotonin and the sleep/wake cycle:
special emphasis on microdialysis studies. Prog. Neurobiol. 60 (1), 13e35.
Portas, C., Grønli, J., 2008. Involvement of the 5-HT1A and the 5-HT1B receptor in the
regulation of sleep and waking. In: Monti, J.M., Pandi-Perumal, S.R., Jacobs, B.L.,
Nutt, D.J. (Eds.), Serotonin and Sleep: Molecular, Functional and Clinical Aspects.
Birkh€auser Basel, pp. 325e369.
M. Chazalon et al. / Neuropharmacology 138 (2018) 315e330330Rasmussen, K., Heym, J., Jacobs, B.L., 1984. Activity of serotonin-containing neurons
in nucleus centralis superior of freely moving cats. Exp. Neurol. 83 (2), 302e317.
Riad, M., Garcia, S., Watkins, K.C., Jodoin, N., Doucet, E., Langlois, X., et al., 2000.
Somatodendritic localization of 5-HT1A and preterminal axonal localization of
5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol. 417 (2), 181e194.
Sahly, I., Fabre, V., Vyas, S., Milet, A., Rouzeau, J.D., Hamon, M., et al., 2007. 5-HT1A-
iCre, a new transgenic mouse line for genetic analyses of the serotonergic
pathway. Mol. Cell. Neurosci. 36 (1), 27e35.
Sakai, K., 2011. Sleep-waking discharge proﬁles of dorsal raphe nucleus neurons in
mice. Neuroscience 197, 200e224.
Sakai, K., Crochet, S., 2001. Role of dorsal raphe neurons in paradoxical sleep gen-
eration in the cat: no evidence for a serotonergic mechanism. Eur. J. Neurosci. 13
(1), 103e112.
Sakai, K., El Mansari, M., Lin, J.S., Zhang, J.G., Vanni Mercier, G., 1990. The posterior
hypothalamus in the regulation of wakefulness and paradoxical sleep. In:
Mancia, M., Marini, G. (Eds.), The Diencephalon and Sleep. Raven Press, New
York, pp. 171e198.
Sanford, L.D., Tejani-Butt, S.M., Ross, R.J., Morrison, A.R., 1996. Elicited PGO waves in
rats: lack of 5-HT1A inhibition in putative pontine generator region. Pharmacol.
Biochem. Behav. 53 (2), 323e327.
Saunders, R.C., Vann, S.D., Aggleton, J.P., 2012. Projections from Gudden's tegmental
nuclei to the mammillary body region in the cynomolgus monkey (Macaca
fascicularis). J. Comp. Neurol. 520 (6), 1128e1145.
Sharp, P.E., Tinkelman, A., Cho, J., 2001. Angular velocity and head direction signals
recorded from the dorsal tegmental nucleus of Gudden in the rat: implications
for path integration in the head direction cell circuit. Behav. Neurosci. 115 (3),
571e588.
Shibata, H., 1987. Ascending projections to the mammillary nuclei in the rat: a study
using retrograde and anterograde transport of wheat germ agglutinin conju-
gated to horseradish peroxidase. J. Comp. Neurol. 264 (2), 205e215.
Slater, I.H., Jones, G.T., Moore, R.A., 1978. Inhibition of REM sleep by ﬂuoxetine, a
speciﬁc inhibitor of serotonin uptake. Neuropharmacology 17 (6), 383e389.
Sommerfelt, L., Hauge, E.R., Ursin, R., 1987. Similar effect on REM sleep but differ-
ential effect on slow wave sleep of the two 5-HT uptake inhibitors zimeldineand alaproclate in cats and rats. J. Neural. Transm. 68 (1e2), 127e144.
Sotelo, C., Cholley, B., El Mestikawy, S., Gozlan, H., Hamon, M., 1990. Direct Immu-
nohistochemical evidence of the existence of 5-HT1A autoreceptors on seroto-
ninergic neurons in the midbrain raphe nuclei. Eur. J. Neurosci. 2 (12),
1144e1154.
Steininger, T.L., Alam, M.N., Gong, H., Szymusiak, R., McGinty, D., 1999. Sleep-waking
discharge of neurons in the posterior lateral hypothalamus of the albino rat.
Brain Res. 840 (1e2), 138e147.
Takahashi, K., Lin, J.S., Sakai, K., 2006. Neuronal activity of histaminergic tuber-
omammillary neurons during wake-sleep states in the mouse. J. Neurosci. 26
(40), 10292e10298.
Taube, J.S., 2007. The head direction signal: origins and sensory-motor integration.
Annu. Rev. Neurosci. 30, 181e207.
Thakkar, M.M., Strecker, R.E., McCarley, R.W., 1998. Behavioral state control through
differential serotonergic inhibition in the mesopontine cholinergic nuclei: a
simultaneous unit recording and microdialysis study. J. Neurosci. 18 (14),
5490e5497.
Tissier, M.H., Lainey, E., Fattaccini, C.M., Hamon, M., Adrien, J., 1993. Effects of
ipsapirone, a 5-HT1A agonist, on sleep/wakefulness cycles: probable post-
synaptic action. J. Sleep Res. 2 (2), 103e109.
Vanni-Mercier, G., Gigout, S., Debilly, G., Lin, J.S., 2003. Waking selective neurons in
the posterior hypothalamus and their response to histamine H3-receptor li-
gands: an electrophysiological study in freely moving cats. Behav. Brain Res. 144
(1e2), 227e241.
Viereckel, T., Dumas, S., Smith-Anttila, C.J., Vlcek, B., Bimpisidis, Z., Lagerstr€om, M.C.,
Konradsson-Geuken, Å., Wallen-Mackenzie, Å., 2016. Midbrain gene screening
identiﬁes a new mesoaccumbal glutamatergic pathway and a marker for
dopamine cells neuroprotected in Parkinson's disease. Sci. Rep. 6, 35203.
Weber, F., Chung, S., Beier, K.T., Xu, M., Luo, L., Dan, Y., 2015. Control of REM sleep by
ventral medulla GABAergic neurons. Nature 526 (7573), 435e438.
Wirtshafter, D., Stratford, T.R., 1993. Evidence for GABAergic projections from the
tegmental nuclei of Gudden to the mammillary body in the rat. Brain Res. 630
(1e2), 188e194.
